Association of bowel radiation dose-volume with skeletal muscle loss during pelvic intensity-modulated radiotherapy in cervical cancer
- PMID: 33712910
- DOI: 10.1007/s00520-021-06131-x
Association of bowel radiation dose-volume with skeletal muscle loss during pelvic intensity-modulated radiotherapy in cervical cancer
Erratum in
-
Correction to: Association of bowel radiation dose-volume with skeletal muscle loss during pelvic intensity-modulated radiotherapy in cervical cancer.Support Care Cancer. 2022 Feb;30(2):1893-1894. doi: 10.1007/s00520-021-06709-5. Support Care Cancer. 2022. PMID: 34820711 No abstract available.
Abstract
Background: Radiation-induced bowel damage may compromise nutrient absorption and digestion and affect body composition during pelvic radiotherapy in patients with locally advanced cervical cancer (LACC). This study aimed to evaluate the relationship between bowel radiation dose-volume and body composition changes during pelvic radiotherapy.
Methods: Data of 301 LACC patients treated with chemoradiotherapy were analyzed. Changes in skeletal muscle index (SMI) and density (SMD), and total adipose tissue index (TATI) were measured from computed tomography images at the L3 vertebral level. A reduction in SMI, SMD, or TATI of ≥10% was classified as "loss." Bowel V45 indicates the bowel volume (mL) receiving a radiation dose of ≥45 Gy. The relationship between body composition and bowel V45 was analyzed using logistic regression models.
Results: After treatment, 61 (20.3%), 81 (26.9%), and 97 (32.2%) patients experienced SMI, SMD, and TATI loss, respectively. Increased bowel V45 was independently associated with increased odds of SMI loss (odds ratio [OR]: 1.012; 95% confidence interval [CI]: 1.007-1.018; p<0.001) and TATI loss (OR: 1.006; 95% CI: 1.001-1.010; p=0.01), but not with SMD loss (OR: 1.005; 95% CI: 1.000-1.009; p=0.054). The cut-off value with the highest accuracy for predicting SMI loss was V45 ≥222 mL; a higher rate of SMI loss was noted in 40.0% of patients with V45 ≥222 mL than in 13.7% of patients with V45 <222 mL (p<0.001).
Conclusions: Higher bowel dose-volume was significantly associated with muscle loss during pelvic radiotherapy. Bowel dose-volume consideration is required in individualized nutritional counseling and supportive care in clinical practice.
Keywords: Bowel dose; Cervical cancer; Computed tomography; Radiotherapy; Sarcopenia.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Wedlake LJ (2018) Nutritional strategies to prevent gastrointestinal toxicity during pelvic radiotherapy. Proc Nutr Soc 77:357–368 - DOI
-
- Kuku S, Fragkos C, McCormack M, Forbes A (2013) Radiation-induced bowel injury: the impact of radiotherapy on survivorship after treatment for gynaecological cancers. Br J Cancer 109:1504–1512 - DOI
-
- Nicholas S, Chen L, Choflet A, Fader A, Guss Z, Hazell S, Song DY, Tran PT, Viswanathan AN (2017) Pelvic radiation and normal tissue toxicity. Semin Radiat Oncol 27:358–369 - DOI
-
- Viswanathan AN, Lee LJ, Eswara JR, Horowitz NS, Konstantinopoulos PA, Mirabeau-Beale KL, Rose BS, von Keudell AG, Wo JY (2014) Complications of pelvic radiation in patients treated for gynecologic malignancies. Cancer 120:3870–3883 - DOI
-
- Jensen NBK, Pötter R, Kirchheiner K, Fokdal L, Lindegaard JC, Kirisits C, Mazeron R, Mahantshetty U, Jürgenliemk-Schulz IM, Segedin B, Hoskin P, Tanderup K, EMBRACE Collaborative Group (2018) Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: physician- and patient reported outcome from the EMBRACE study. Radiother Oncol 127:431–439 - DOI
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
